Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $351.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target increased by Citigroup from $338.00 to $351.00 in a research report sent to investors on Friday,Benzinga reports. Citigroup currently has a buy rating on the biopharmaceutical company’s stock.

A number of other brokerages have also commented on ALNY. Royal Bank of Canada lifted their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a research report on Friday. StockNews.com cut Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. Sanford C. Bernstein lowered their price target on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, Canaccord Genuity Group upped their price target on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the company a “buy” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $283.34 on Friday. The stock has a 50-day moving average price of $257.16 and a 200 day moving average price of $259.74. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The firm has a market cap of $36.68 billion, a price-to-earnings ratio of -130.57 and a beta of 0.39. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). Research analysts expect that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, Director Phillip A. Sharp sold 11,250 shares of the company’s stock in a transaction that occurred on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. This represents a 10.06 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock valued at $19,958,097 in the last quarter. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Larson Financial Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares in the last quarter. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $28,000. R Squared Ltd bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $33,000. OFI Invest Asset Management bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Finally, Colonial Trust Co SC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $35,000. Institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.